Superantigen-targeted therapy: Phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies

Clinical Cancer Research

Volumn 4, Issue 8, 1998, Pages 1903-1914

  Alpaugh, R Katherine ^a   Schultz, Josephine ^a   McAleer, Cecelia ^a   Giantonio, Bruce J ^b   Persson, Robert ^c   Burnite, Marie ^a   Nielsen, Sven Erik ^e   Vitek, Lauren ^d   Persson, Bo ^c   Weiner, Louis M ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c Pharmacia & Upjohn AB   (Sweden)

^d PFIZER INC   (United States)

^e Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYBRID PROTEIN; NACOLOMAB TAFENATOX; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG SCREENING; FEMALE; FEVER; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MALE; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENTEROTOXINS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; INFUSIONS, INTRAVENOUS; INTERFERON INDUCERS; MALE; MIDDLE AGED; SUPERANTIGENS;

EID: 0031870976     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Kotb, M. Bacterial pyrogenic exotoxins as superantigens. Clin. Micro. Rev., 8: 411-426, 1995.
2. Wynn, T. A., Reynolds, A., James, S., Cheever, A. W., Caspar, P., Hieny, S., Jankovic, D., Strand, M., and Sher, A. IL-12 enhances vaccine-induced immunity to schistosomes by augmenting both humoral and cell-mediated immune responses against the parasite. J. Immunol., 157: 4068-4078, 1996.
3. Melder, R. J., Rosenfeld, C. S., Herberman, R. B., and Whiteside, T. L. Large scale preparation of adherent lymphokine-activated killer (A-LAK) cells for adoptive immunotherapy in man. Cancer Immunol. Immunother., 29: 67-73, 1989.
4. Rosenberg, S. E., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C. G., and White, D. E. A progress report on treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med., 316: 889-897, 1987.
5. Chatenoud, L., Ferran, C., Legendre, C., Thovard, I., Merite, S., Reuter, A., Gevaert, Y., Kreis, H., Franchimort, P., and Bach, J. F. In vivo activation following OKT3 administration. Transplantation (Baltimore), 49: 697-702, 1990.
6. Weiner, L. M., Clark, J. I., Davey, M., Li, W. S., Garcia de Palazzo, I., Ring, D. B., and Alpaugh, R. K. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII. Cancer Res., 55: 4586-4593, 1995.
7. Bodey, B., Siegel, S. E., and Kaiser, H. E. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Anticancer Res., 16: 661-674, 1996.
8. Tiedemann, R. E., and Fraser, J. D. Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation. J. Immunol., 157: 3958-3966, 1996.
9. Abrahmsén, L., Dohlsten, M., Segrén, S., Björk, P., Jonsson, E., and Kalland, T. Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J., 14: 2978-2986, 1995.
10. Kozono, H., Parker, D., White, J., Marrack, P., and Kappler, J. Multiple binding sites for bacterial superantigens on soluble class II MHC molecules. Immunity, 3: 187-196, 1995.
11. Hudson, K. R., Tiedemann, R. E., Urban, R. G., Lowe, S. C., Strominger, J. L., and Fraser, J. D. Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II. J. Exp. Med., 182: 711-720, 1995.
12. Newton, D. W., Dohlsten, M., Olsson, C., Segrén, S., Lundin, K. E. A., Lando, P. A., Kalland, T., and Kotb, M. Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vβ specificity. J. Immunol., 157: 3988-3994, 1996.
13. Fleischer, B., Gerardy-Schan, R., Metzroth, B., Carrel, S., Gerlach, D., and Kohler, W. An evolutionary conserved mechanism of T cell activation by microbial toxins. Evidence for different affinities of T cell receptor-toxin interaction. J. Immunol., 146: 11-17, 1991.
14. Irwin, M. J., Hudson, K. R., Fraser, J. D., and Gascoigne, N. R. J. Enterotoxin residues determining T-cell receptor Vβ binding specificity. Nature (Lond.), 359: 841-843, 1992.
15. Fraser, J. D. High affinity binding sites of staphylococcal enterotoxins A and B to HLA-DR. Nature (Lond.), 339: 221-224, 1989.
16. Fischer, H., Dohlsten, M., Lindvall, M., Sjögren, H. O., and Carlsson, R. Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines. J. Immunol., 142: 3151-3155, 1989.
17. Dellabona, P., Peccoud, J., Kappler, J., Marrack, P., and Mathis, D. Superantigens interact with MHC class II molecules outside of the antigen groove. Cell, 62: 1115-1121, 1990.
18. Jardetzky, T. S., Brown, J. H., Gorga, J. C., Stern, L. J., Urban, R. G., Chi, Y., Stauffacher, C., Strominger, J. L., and Wiley, D. C. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature (Lond.), 368: 711-718, 1994.
19. Malchiodi, E. L., Eisenstein, E., Fields, B. A., Ohlendorf, D. H., Schlievert, P. M., Karjalainen, K., and Mariuzza, R. A. Superantigen binding to a T cell receptor β chain of known three-dimensional structure. J. Exp. Med., 182: 1833-1845, 1995.
20. Seth, A., Stern, L. J., Ottenhoff, T. H. M., Engel, I., Owen, M. J., Lamb, J. R., Klausner, R. D., and Wiley, D. C. Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitro. Nature (Lond.), 369: 324-327, 1994.
21. Dohlsten, M., Lando, P. A., Hedlund, G., Trowsdale, J., and Kalland, T. Targeting of human cytotoxic T lymphocytes to MHC class II expressing cells by staphylococcal enterotoxins. Immunology, 71: 96-100, 1990.
22. Hermann, T., Maryanski, J. L., Romero, P., Fleischer, B., and MacDonald, H. R. Activation of MHC class I restricted CD8+ CTL by microbial T cell mitogens. Dependence upon MHC class II expression of the target cells and Vβ usage of the responder T cell. J. Immunol., 144: 1181-1186, 1990.
23. Kalland, T., Hedlund, G., Dohlsten, M., and Lando, P. A. Staphylococcal enterotoxin-dependent cell-mediated cytotoxicity. Curr. Topics Microbiol. Immunol., 174: 81-92, 1991.
24. Hedlund, G., Dohlsten, M., Petersson, C., and Kalland, T. Superantigen based tumor therapy: in vivo activation of cytotoxic T cells. Cancer Immunol. Immunother., 36: 89-93, 1993.
25. Fleischer, B., and Schrezenmeier, H. Stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for MHC class II molecules on accessory cells. J. Exp. Med., 167: 1697-1708, 1988.
26. Dohlsten, M., Sundstedt, A., Björklund, M., Hedlund, G., and Kalland, T. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int. J. Cancer, 54: 482-488, 1993.
27. Dohlsten, M., Abrahmsén, L., Björk, P., Lando, P., Hedlund, G., Forsberg, G., Brodin, T., Gascoigne, N. R. J., Forberg, C., Lind, P., and Kalland, T. Monoclonal antibody-superantigen fusion proteins: tumor specific agents for T-cell based tumor therapy. Proc. Natl. Acad. Sci. USA, 91: 8945-8949, 1994.
28. Dohlsten, M., Hedlund, G., Akerblom, E., Lando, P. A., and Kalland, T. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc. Natl. Acad. Sci. USA, 88: 9287-9291, 1991.
29. Lando, P. A., Dohlsten, M., Hedlund, G., Akerblom, E., and Kalland, T. T cell killing of human colon carcinomas by monoclonal-antibody targeted superantigens. Cancer Immunol. Immunother., 36: 223-228, 1993.
30. Lando, P. A., Hedlund, G., Dohlsten, M., and Kalland, T. Bacterial superantigens as anti-tumor agents: induction of tumor cytotoxicity in human lymphocytes by staphylococcal enterotoxin A. Cancer Immunol. Immunother., 3: 231-237, 1991.
31. Dohlsten, M., Lando, P. A., Björk, P., Abrahmsén, L., Ohlsson, L., Lind, P., and Kalland, T. Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol. Immunother., 41: 162-168, 1995.
32. Gidlöf, C., Dohlsten, M., Kalland, T., and Tötterman, T. H. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells. Leukemia (Baltimore), 9: 1534-1542, 1995.
33. Giantonio, B. J., Alpaugh, R. K., Schultz, J., McAleer, C., Newton, D. W., Shannon, B., Guedez, Y., Kotb, M., Vitek, L., Persson, R., Gunnarsson, P-O., Kalland, T., Dohlsten, M., Persson, B., and Weiner, L. M. Superantigen-based immunotherapy: a Phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J. Clin. Oncol., 15: 1994-2007, 1997.
34. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
35. Wen, R., Blackman, M. A., and Woodland, D. L. Variable influence of MHC polymorphism on the recognition of bacterial superantigens by T cells. J. Immunol., 155: 1884-1892, 1995.
36. Ohnishi, H., Ledbetter, J. A., Kanner, S. B., Linsley, P. S., Tanaka, T., Geller, A. M., and Kotb, M. CD28 cross-linking augments TCR-mediated signals and costimulates superantigen responses. J. Immunol., 154: 3180-3193, 1995.
37. Herman, A., Labrecque, N., Thibodeau, J., Marrack, P., Kappler, J. W., and Sekaly, R. P Identification of the staphylococcal enterotoxin A superantigen binding site in the beta 1 domain of the human histocompatibility antigen HLA-DR. Proc. Natl. Acad. Sci. USA, 88: 9954-9958, 1991.
38. Karp, D. R., and Long, E. O. Identification of HLA-DR1 beta chain residues critical for binding staphylococcal enterotoxins A and E. J. Exp. Med., 175: 415-424, 1992.
39. Kalland, T., Dohlsten, M., Lando, P. A., Abrahmsén, L., Björk, P., Hedlund, G., Ohlsson, L., Brodin, T., and Hansson, J. Antibody targeted superantigens in experimental tumor therapy. In: J. Thibodeau and R. P. Sekaly (eds), Bacterial Superantigens: Structure, Function and Therapeutic Potential, pp. 219-238. Austin, TX: Landes Co., 1995.
40. Holzer, U., Orlikowsky, T., Zehrer, C., Bethge, W., Dohlsten, M., Kalland, T., Niethammer, D., and Dannecker, G. E. T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant. Immunology, 90: 74-80, 1997.
41. Lando, P. A., Olsson, C., Kalland, T., Newton, D., Kotb, M., and Dohlsten, M. Regulation and superantigen-induced T cell activation in the absence and presence of MHC class II. J. Immunol., 157: 2857-2863, 1996.